Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same author

Comprehensive lincRNA Transcriptome in Acute Myeloid Leukemia: Integrating Known and Newly Identified lincRNAs Across Pediatric and Adult Cohorts.

Non-coding RNA·2026
Same author

Reagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays.

Clinical chemistry and laboratory medicine·2026
Same author

Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.

Research and practice in thrombosis and haemostasis·2026
Same author

Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort.

Thrombosis research·2026

Related Experiment Video

Updated: May 15, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Monitoring Extended Half-Life Factor VIII and IX Concentrates: Performance in Routine Clotting-and Thrombin

An K Stroobants1,2,3, Eva-Leonne Göttgens1,4, Yvonne M C Henskens2,5

  • 1Department of Laboratory Medicine, Laboratory of Hematology, Radboudumc, Nijmegen, the Netherlands.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 14, 2026
PubMed
Summary
This summary is machine-generated.

Monitoring extended half-life (EHL) factor VIII and factor IX products using laboratory assays is complex. Many assays lack accuracy, and their results may not reflect the true haemostatic potential of EHL products.

Keywords:
EHLExtended half‐lifeFactor IXFactor VIIIlaboratory testingthrombin generation

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Related Experiment Videos

Last Updated: May 15, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Area of Science:

  • Pharmacology
  • Biochemistry
  • Hematology

Background:

  • Monitoring extended half-life (EHL) factor VIII (FVIII) and factor IX (FIX) products presents challenges due to assay variability.
  • Discrepant results from different laboratory assays complicate accurate product assessment.

Purpose of the Study:

  • To evaluate the accuracy of various laboratory assays for EHL FVIII and FIX products.
  • To reassess existing data and present new findings from EHL spiking experiments and thrombin generation (TG) assays.

Main Methods:

  • Re-assessed published data on EHL-assay combinations using uniform bias cutoffs.
  • Determined accuracy for six FVIII assays (efmoroctocog alfa, rurioctocog alfa pegol) and four FIX assays (eftrenonacog alfa, albutrepenonacog alfa, nonacog bèta pegol).
  • Evaluated haemostatic potential using thrombin generation (TG) assays on spiked samples.

Main Results:

  • Many EHL-FVIII/FIX assay combinations demonstrated insufficient accuracy.
  • Nine new EHL-assay combinations failed to meet accuracy criteria across the tested factor activity range.
  • Thrombin generation assays indicated that the haemostatic potential of some EHL products may differ from their labeled potency.

Conclusions:

  • Routine FVIII and FIX assays often lack the necessary accuracy for reliable EHL product monitoring.
  • Careful selection of appropriate laboratory assays is crucial for accurate EHL product characterization.
  • Thrombin generation results suggest potential discrepancies between labeled potency and actual haemostatic potential for EHL products.